Table 1 Clinical characteristics of HEV-associated GBS
From: Guillain-Barre syndrome caused by hepatitis E infection: case report and literature review
Reference | Country | No. of cases | Age | Sex | Delay hepatitis neurological manifestation | Nerve conduction study | Anti-glycoprotein antibody | IgM | HEV RNA | HEV genotype | ALT (IU/L) | CSF | Treatment | Recovery/Delay | Comorbidity | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bilirubin(μmol/L) | Protein level, mg/dL | Cell count (×10^6/L) | |||||||||||||||
Sood 2000 [13] | India | 1 | 50 | M | 5 days | AIDP | NT | + | NT | NT | 114 | 242.82 | 186 | 0 | Supportive | Full/1 month | None |
Kumar 2002 [16] | India | 1 | 35 | M | 17 days | AMSAN | NT | + | NT | NT | 752 | 91.8 | NT | NT | MV/IVIg | Full/2 weeks | None |
Kamani 2005 [12] | India | 1 | 58 | F | 9 days | NT | NT | + | NT | NT | 1448 | 40.7 | 80 | 2 | IVIg/PP | Full/12 days | None |
Khanam 2008 [19] | Bangladesh | 1 | 20 | M | 10 days | AIDP&AMSAN | NT | + | NT | NT | 2509 | 61.56 | 190 | 0 | MV | Full/12 days | None |
Loly 2009 [14] | Belgium | 1 | 66 | M | Few days | AIDP | GM2+ | + | NT | NT | 1813 | NM | 172.2 | NM | IVIg | Full/4 months | None |
Cronin 2011 [15] | Ireland | 1 | 40 | M | Concomitant | AIDP | GM2+ | + | NT | NT | 57 | NM | >500 | 0 | MV/IVIg/PP | Full/6 months | None |
Kamar 2011 [7] | France | 1 | 60 | F | Concomitant | AIDP | NT | + | Serum+ CSF- | 3f | 384 | 35 | 200 | 14 | IVIg | Partial/18 months | None |
Maurissen 2012 [17] | Belgium | 1 | 51 | F | Concomitant | AIDP | GM1&GM2+ | + | Serum+ | NT | 2704 | NM | 61 | 15 | IVIg | Full/1 week | None |
Del Bello 2012 [20] | France | 1 | 65 | M | Concomitant | AIDP | NT | + | Serum+ | 3f | 2000 | NM | 64 | 0 | MV/IVIg/Ribavirin | partial/2 month | Severe myositis |
Tse 2012 [21] | Hong Kong | 1 | 60 | F | 3 days | AIDP | NT | + | NT | NT | 2858 | 60 | NM | NM | PP | Full/1 month | None |
Santos 2013 [22] | Portugal | 1 | 58 | M | 17 days | AIDP | NT | + | Serum+ | 3a | 2320 | 114.74 | 181 | 4 | MV/IVIg | partial/2 month | None |
Sharma 2013 [23] | India | 1 | 27 | M | 40 days | AIDP | NT | + | NT | NT | NM | NM | 243 | <5 | IVIg | Full/NM | None |
Geurtsvan-Kessel 2013 [24] | Bangladesh | 11 | mean: 24 | NM | NM | NM | NT | + | Serum+(n = 1) | 1(n = 1) | NM | NM | NM | NM | NM | NM | None |
van den Berg 2014 [25] | Netherlands | 10 | mean: 54 | 6 M, 4F | Mean: 5 days | AIDP(n = 5) AMAN(n = 1) AMSAN(n = 1) Equivocal(n = 2) Inexcitable(n = 1) | NT | + | Serum+(n = 3) CSF-(n = 10) | 3 | Mean: 160.9 | Mean: 13.3 | NM | Mean:4.2 | NM | NM | NM |
Chen 2014 [26] | China | 1 | 64 | M | 5 days | AIDP | GM2+ | + | NT | NT | 1461 | 156.9 | 88 | 10 | MV/IVIg | Full/12 months | Encephalitis |
Scharn 2014 [27] | Germany | 1 | 50 | M | 7 days | AIDP & AMAN | – | + | Serum+ CSF- | 3c | 334 | NM | 81 | <1 | IVIg | Partial/5 months | None |
Woolson 2014 [28] | NM | 1 | 42 | M | NM | NM | NT | + | Serum+ | 3 | 623 | 16 | 127 | 145 | NM | Full/3 months | None |
Comont 2014 [29] | France | 1 | 73 | M | Concomitant | NM | GM1+ | + | Serum+ CSF+ | 3f | 822 | 101 | 137 | NM | IVIg | Full/2 months | None |
Bandyopadhyay 2015 [30] | Japan | 1 | 43 | F | 14 days | AIDP & AMAN | GM1+ | + | Serum+CSF- | 3 | 1950 | 85.5 | 350 | 12 | MV/IVIg | Partial/NM | None |
Higuchi 2015 [31] | Japan | 1 | 49 | M | 10 days | AIDP | – | + | Serum+ | 3 | 1246 | 15.4 | 102 | 7 | IVIg | Full/3 months | None |
Perrin 2015 [32] | France | 2 | Mean: 57 | 1F, 1 M | Few days | AIDP | NT | + | Serum+(n = 1) | 3f | Mean:216 | Mean:20.6 | Mean:173 | NM | IVIg | Partial (n = 2)/Mean: 9 weeks | None |
Fukae 2016 [33] | Japan | 3 | Mean: 53 | 3 M | NM | AIDP(n = 1) MSF(n = 1) | GM1 + (n = 1) GQ1b + (n = 1) | + | Serum+(n = 1) | NT | Mean: 230.3 | NM | Mean: 91 | Mean:5 | IVIg | Full (n = 2) partial(n = 1)/NM | None |
Ji 2016 [34] | South Korea | 1 | 58 | M | 75 days | NM | NT | + | NT | NT | 525 | 23.59 | 44.6 | 0 | IVIg | Full/12 months | None |
Lei 2017 [35] | China | 1 | 30 | M | Concomitant | AIDP | NT | + | NT | NT | 4502 | 83.96 | 344.19 | 0 | IVIg | Full/3 months | None |
Stevens 2017 [36] | Belgium | 6 | Mean:61 | 4 M, 2F | NM | AIDP(n = 1) AMSAN(n = 1) Equivocal(n = 1) Demyelinating(n = 2) Sensory neuropathy(n = 1) | – | + | Serum+(n = 2) | NT | Mean:762 | Mean:39.27 | Mean:69.4 | Mean:4.8 | IVIg(n = 4) PP(n = 1) supportive(n = 1) | Partial (n = 5)/3–6 months Death(n = 1)/1 month | NM |
Our case | China | 1 | 58 | M | 11 days | AIDP | – | + | NT | NT | 664 | 51.8 | 275.3 | 0 | IVIg | Full/6 months | None |